Full Text View
Tabular View
No Study Results Posted
Related Studies
Scleroderma Registry
This study is currently recruiting participants.
Study NCT00074568   Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: December 16, 2003   Last Updated: May 8, 2009   History of Changes

December 16, 2003
May 8, 2009
September 2000
 
 
 
Complete list of historical versions of study NCT00074568 on ClinicalTrials.gov Archive Site
 
 
 
Scleroderma Registry
Scleroderma Family Registry and DNA Repository

Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition. The Scleroderma Registry will conduct genetic analyses for disease-related genes in patients with scleroderma and their family members (parents, brothers, and sisters).

Scleroderma refers to a group of diseases that involve the abnormal growth of connective tissue, which supports the skin and internal organs. Scleroderma can affect the skin, making it hard and tight; it can also damage the blood vessels and internal organs such as the heart, lungs, and kidneys. Estimates for the number of people in the United States with the systemic (body-wide) form of scleroderma range from 40,000 to 165,000. The number of people with all scleroderma-related disorders is between 250,000 and 992,500.

Researchers believe that several factors interact to produce scleroderma, including abnormal immune activity, potential environmental triggers, and genetic makeup. Scleroderma is not passed on from parents to child, but certain genes may make a person more likely to develop the disease. The goals of this project are to identify the genes that influence disease susceptibility and expression in systemic scleroderma and to establish a repository of DNA, plasma, and serum samples from single case scleroderma families, multicase families, and healthy unrelated volunteers for the use of researchers interested in studying this disease.

Participants in the Registry will have a phone interview regarding disease characteristics and family history. Participants will be sent a blood kit to get a blood sample drawn locally for shipment to the Registry lab. Blood samples will be made available (anonymously) for studies by researchers around the country. In some cases, participants will be asked to sign a release of medical information so that medical records can be obtained to verify the diagnosis.

As of May 2009, this study is no longer enrolling family members.

 
Observational
Case Control, Prospective
  • Systemic Sclerosis
  • Scleroderma
 
  • Patients with scleroderma and their family members (parents, brothers, and sisters)
  • Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
5000
 
 

Inclusion Criteria

  • Diagnosis of systemic sclerosis or family members of patients with systemic sclerosis

Or

  • Healthy volunteer with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
Both
 
Yes
Contact: Jason Anderson 713-500-7196
United States
 
NCT00074568
Maureen D. Mayes MD MPH, University of Texas Health Science Center Houston
NIAMS-108, NO1-AR-0-2251
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The University of Texas Health Science Center, Houston
Principal Investigator: Maureen D. Mayes, MD, MPH The University of Texas Health Science Center, Houston
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP